Results

Total Results: 376 records

Showing results for "renal".

  1. effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-tests-outcomes_methods.pdf
    July 01, 2012 - testing process poses potential harms, including allergic reaction to the intravenous contrast material, renal
  2. effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_research-protocol.pdf
    March 09, 2010 - Privigen 10% Vivaglobin Interaction with activating Fc receptors; biologic No Hepatitis; acute renal
  3. effectivehealthcare.ahrq.gov/sites/default/files/pdf/lung-cancer-staging_research-protocol.pdf
    December 08, 2014 - In addition, some patients cannot receive iodinated contrast material due to renal insufficiency, limiting … previously noted, performance of various imaging modalities may be impacted by comorbidities such renal
  4. effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_appendixes.pdf
    October 06, 2006 - Procedural non-fatal MI %* Freedom from Stroke % NI %** CHF % Respiratory failurea % Renal … Procedural non-fatal MI %* Freedom from Stroke % NI %** CHF % Respiratory failurea % Renal … ο Calculated N Bleeding requiring a transfusion ο Calculated N Renal … outcomes: We are interested in CHF, stroke, respiratory failure or other pulmonary complications, renal
  5. effectivehealthcare.ahrq.gov/sites/default/files/coronary-artery-disease-testing_executive.pdf
    March 01, 2011 - events • Dysrhythmia Ultimate Health Outcomes Adverse Effects or Harms of Testing Procedural harms: renal … interest for both the index test and any subsequent downstream testing included harms of testing (e.g., renal … groups—procedural stroke (0.02% vs. 0.04%), major bleeding (0.1% in both groups), anaphylaxis or renal … There were no cases of post-test renal dysfunction (low strength of evidence). … unstable angina; or a major procedural complication, such as stroke, major bleeding, anaphylaxis, or renal
  6. effectivehealthcare.ahrq.gov/sites/default/files/lung-cancer-staging_executive.pdf
    April 01, 2016 - In addition, some patients cannot receive iodinated contrast material due to allergy or renal insufficiency … patient subgroups, performance of various imaging modalities may be affected by comorbidities such renal
  7. effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/pdf/epc-year-in-review-2020.pdf
    January 01, 2020 - End-stage Renal Disease in the Medicare Population: Frequency and Duration of Hemodialysis and Quality
  8. effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-disposition-120516.pdf
    October 01, 2011 - observational studies found acetaminophen associated with modest increases in blood pressure or higher risk of renal … Hypertension is the second leading cause of kidney failure or End Stage Renal Disease in the United … Effects of NSAIDs on HTN and renal function are reviewed starting on page 66, line 7. Rosa L.
  9. effectivehealthcare.ahrq.gov/sites/default/files/pdf/opioids-oa-protocol.pdf
    June 29, 2019 - of potential risk factors for harm from opioids, including cognitive impairment, altered hepatic or renal
  10. effectivehealthcare.ahrq.gov/sites/default/files/pdf/topic-brief1-care-coordination.pdf
    April 01, 2021 - or 13 15 6 and 14 16 Medicare/ 17 (medicare or disabled or disabilit* or kidney or renal
  11. effectivehealthcare.ahrq.gov/sites/default/files/related_files/topic-brief1-care-coordination.pdf
    April 01, 2021 - or 13 15 6 and 14 16 Medicare/ 17 (medicare or disabled or disabilit* or kidney or renal
  12. effectivehealthcare.ahrq.gov/sites/default/files/ch_3-user-guide-to-ocer_130129.pdf
    September 21, 2012 - variables (e.g., timing after stroke, stable or unstable angina); (3) comorbidities (e.g., presence of renal
  13. effectivehealthcare.ahrq.gov/sites/default/files/related_files/alcohol-misuse-drug-therapy_executive.pdf
    January 27, 2012 - Acamprosate is contraindicated for people with severe renal impairment and requires dose adjustments … for moderate renal impairment.
  14. effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-drugs-utilization-cost_research.pdf
    January 01, 2011 - Administration (FDA) has labeled peginterferon alfa-2a for use in hepatitis, off-label uses include renal
  15. effectivehealthcare.ahrq.gov/sites/default/files/pdf/cystic-fibrosis-hgh_research-protocol.pdf
    August 22, 2008 - growth hormone deficiency, idiopathic short stature, Turner syndrome, Prader-Willi Syndrome, chronic renal
  16. effectivehealthcare.ahrq.gov/sites/default/files/pdf/patient-family-engagement-protocol.pdf
    December 31, 2019 - Abbreviations: DM=diabetes, HTN=hypertension, IT=information technology, ER=emergency room; ESRD=end stage renal
  17. Layout 1 (pdf file)

    effectivehealthcare.ahrq.gov/sites/default/files/related_files/type-2-diabetes-insulin_executive.pdf
    September 01, 2008 - All trials either excluded patients with cardiac, renal, or hepatic disease or did not report whether
  18. effectivehealthcare.ahrq.gov/sites/default/files/related_files/preterm-birth-terbutaline-pump_disposition-comments.pdf
    September 01, 2011 - basal amount of drug without pharmacologic consultation regarding volume distribution, body mass and renal
  19. effectivehealthcare.ahrq.gov/sites/default/files/pdf/skin-cancer_research-protocol.pdf
    August 10, 2016 - limited life expectancy (e.g., the very elderly, those with terminal cancer, those with end stage renal
  20. effectivehealthcare.ahrq.gov/sites/default/files/mcda_webinar_transcript2.pdf
    August 27, 2012 - The gain for going from five months to ten months in progression free survival in renal cell carcinoma … specific question for you, Reed, is how do you manage to get patient input on things like treatment for renal

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: